The restructuring of cardiovascular drugmaker Amarin means the layoff of about 30% of staff. Sales of Vascepa, the company’s only commercialized product, have suffered as generic versions gain traction in the market.
An analyst wrote that a best-case scenario for Amarin is that it may take 2-3 years for generic versions of Vascepa to hit the market. But the company has likely lost its luster as an acquisition target.
AI-native tax firm Gelt combines top human tax experts with AI to help physicians and healthcare practices use data-driven tax strategies to lower liabilities, improve profitability, and future-proof their finances.